Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Coca-Cola, Credit Suisse and Philips rise premarket; Bed Bath & Beyond falls

Published 24/04/2023, 10:18 pm
© Reuters
KO
-
PHG
-
CSGN
-
BBBYQ
-
CMCSA
-
RDSa
-
PPG
-
UBS
-
FSLR
-
IXIC
-
CS
-
PHG
-
KC
-
FHTX
-

By Peter Nurse

Investing.com -- Stocks in focus in premarket trade on Monday, April 24th. Please refresh for updates.

  • Bed Bath & Beyond (NASDAQ:BBBY) stock slumped over 35% after the embattled home goods retailer filed for bankruptcy protection, following years of underperformance.

  • Coca-Cola (NYSE:KO) stock rose 1.4% after the soft drinks giant beat expectations for quarterly revenue, as demand for its produce remained resilient in the face of multiple price increases.

  • Philips (NYSE:PHG) ADRs climbed 13.2% after the Dutch health technology company reported much better than expected first quarter results and said it had set aside around $630 million related to lawsuits over its recall of respiratory devices.

  • Credit Suisse (SIX:CSGN) (NYSE:CS) ADRs rose 1.9% after the Swiss lender, in the process of being acquired by rival UBS (NYSE:UBS), up 1.6%, shelved plans to purchase Michael Klein’s investment firm following $68 billion of outflows last quarter.

  • PPG Industries (NYSE:PPG) stock rose 1.8% after JPMorgan upgraded its stance on the industrial coatings supplier to ‘overweight’ from ‘neutral’ following last week’s strong quarterly earnings and upbeat full-year guidance.

  • Comcast (NASDAQ:CMCSA) stock fell 0.2% after the weekend departure of Jeff Shell, the CEO of unit NBCUniversal, following a complaint of an inappropriate relationship with a woman in the company.

  • First Solar (NASDAQ:FSLR) stock fell 2.5% after Citigroup downgraded the solar panel manufacturer to ‘sell’ from ‘neutral’, citing uncertainty surrounding the company’s long-term outlook for margins and growth.

  • Kingsoft Cloud (NASDAQ:KC) stock fell 5.9% after Goldman Sachs downgraded the Chinese software company to ‘sell’ from ‘neutral’ with the stock up nearly 75% year to date.

  • Foghorn Therapeutics (NASDAQ:FHTX) stock fell around 22.9% after the FDA placed a partial clinical hold on the trial of the company’s key cancer drug.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.